Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
BJU International|April 3, 2018
Low-dose-rate brachytherapy for the treatment of localised prostate cancer in men with a high risk of disease relapseRobert Laing, Jennifer Uribe, Santiago Uribe-Lewis, et al.
BJU International|July 4, 2017
Long-term oncological outcomes and toxicity in 597 men aged ≤60 years at time of low-dose-rate brachytherapy for localised prostate cancerStephen E M Langley, Ricardo Soares, Jennifer Uribe, et al.
BJU International|November 10, 2019
Hemi-ablative low-dose-rate prostate brachytherapy for unilateral localised prostate cancerStephen Langley, Jennifer Uribe, Santiago Uribe-Lewis, et al.
BJU International|August 30, 2021
Robot-assisted salvage seminal vesicle excision for isolated recurrence after low-dose-rate prostate brachytherapyStephen Langley, Christopher Eden, Matthew Perry, et al.
BJU International|August 27, 2021
Long-term survival after low-dose-rate brachytherapy for prostate cancer: the Royal Surrey experienceSantiago Uribe-Lewis, Jennifer Uribe, Vincent Bourke, et al.
Brachytherapy|October 7, 2022
Is hemi-gland focal LDR brachytherapy as effective as whole-gland treatment for unilateral prostate cancer?Stephen Langley, Jennifer Uribe, Santiago Uribe-Lewis, et al.
Brachytherapy|March 27, 2024
Net survival of men with localized prostate cancer after LDR brachytherapySantiago Uribe-Lewis, Jennifer Uribe, Claire Deering, et al.
BMC Cancer|January 16, 2019
Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort studyMartin Boegemann, Sara Khaksar, Guillaume Bera, et al.
Lancet (London, England)|October 26, 2018
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trialChristopher C Parker, Nicholas D James, Christopher D Brawley, et al.
Pageof 1